• Joe Hammang

    Senior Director, Worldwide Science Policy

    New York, NY/New London, CT

    I lead a team of scientific professionals who develop policies and provide scientific expertise on the critical science and technology issues facing the biopharmaceutical industry. We support our world wide business units, the US and global Public Affairs teams and the R&D division. We also help manage Pfizer’s relationships with external constituents and key thought leaders in science and medicine to help develop industry-leading policy positions.

    Prior to joining Pfizer’s Science Policy and Public Affairs group in 2002, I served as Vice President for Science, Technology and Business Development at the Rhode Island Economic Development Corporation and as Head of Science and Technology at the Rhode Island Economic Policy Council. In 1999, I was appointed Governor Lincoln Almond’s Advisor for Science and Technology.

    I started my scientific career as a postdoctoral fellow and then as a Research Investigator in Cell and Molecular Neuroscience at Bristol Myers-Squibb in Wallingford, Connecticut where I was involved in Alzheimer’s disease research. Following Bristol Myers-Squibb, I served as Director of Cell and Molecular Neuroscience and Director of the Ophthalmology and stem cell R&D programs at CytoTherapeutics in Providence, Rhode Island.

    Throughout my career, I have authored more than 60 scientific articles and invited book chapters, and invented or co-invented 35 U.S. patents. I completed my graduate work at the University of Wisconsin in 1990, and hold a Ph.D. in the area of Neuroscience.

    Key Areas of Research

    Neuroscience – especially interested in Alzheimer’s Disease and Parkinson’s Disease

    Regenerative medicine and stem cells

    R&D productivity in the biopharmaceutical industry

    Industry transparency initiatives

    Health care disparities

    Professional Affiliations

    Society for Neuroscience

    Published Articles

    Hammang, Joseph P. “Industry and academia must avoid mismatching disclosures.”  Nature Biotechnology 27, 21 (2009)  http://www.nature.com/nbt/journal/v27/n1/full/nbt0109-21a.html